pyrroles has been researched along with Hearing Loss in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bali, S; Bhutta, MF; Brown, SD; Cheeseman, MT; Hilton, H; Hough, TA; Parker, A; Pathak, P; Potter, PK; Purnell, T; Romero, MR; Tyrer, HE; Vizor, L; Vowell, K; Wells, S; Williams, D | 1 |
Alafris, A; Cohen, H; Liu, M; Longo, AJ | 1 |
1 review(s) available for pyrroles and Hearing Loss
Article | Year |
---|---|
Irreversible atorvastatin-associated hearing loss.
Topics: Adult; Atorvastatin; Hearing Loss; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
1 other study(ies) available for pyrroles and Hearing Loss
Article | Year |
---|---|
HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.
Topics: Animals; Blister; Body Fluids; Cell Hypoxia; Disease Models, Animal; Ear, Middle; Gene Expression Regulation; Hearing Loss; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Nitroimidazoles; Otitis Media with Effusion; Phthalazines; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |